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Effect of recombinant human erythropoietin and doxorubicin in combination on the 
proliferation of MCF-7 and MDA-mb231 breast cancer cells 
ABSTRACT 
Patients with cancer often exhibit signs of anemia as the result of the disease. Thus, cancer 
chemotherapies often include erythropoietin (EPO) in the regime to improve the survival rate 
of these patients. The aim of the present study was to determine the effect of EPO on 
doxorubicin-treated breast cancer cells. The cytotoxicity of doxorubicin alone or in 
combination with EPO against the MCF-7 and MDA-MB-231 human breast cancer cells 
were determined using an MTT cell viability assay, neutral red (NR) uptake assay and lactate 
dehydrogenase (LDH) assay. The estimated half maximal inhibitory concentration values for 
doxorubicin and the combination of doxorubicin with EPO were between 0.140 and 
0.260 µg/ml for all cells treated for 72 h. Treatment with doxorubicin in combination with 
EPO led to no notable difference in cytotoxicity, compared with treatment with doxorubicin 
alone. The antiproliferative effect of doxorubicin at a concentration of 1 µg/ml on the 
MDA-MB-231 cells was demonstrated by the decrease in viable cells from 3.6x10(5) at 24 h 
to 2.1x10(5) at 72 h of treatment. In order to confirm apoptosis in the doxorubicin-treated 
cells, the activities of caspases-3/7 and -9 were determined using a TBE assay. The results 
indicated that the activities of caspases-3/7 and -9 were significantly elevated in the 
doxorubicin-treated MDA-MB-231 cells by 571 and 645%, respectively, and in the MCF 7 
cells by 471 and 345%, respectively, compared with the control cells. EPO did not modify the 
effect of doxorubicin on these cell lines. The results of the present study suggested that EPO 
was safe for use in combination with doxorubicin in the treatment of patients with breast 
cancer and concurrent anemia. 
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